Expert-level pharmacological comparison of Tirzepatide (dual GIP/GLP-1), Retatrutide (triple agonist), and Tesamorelin (GHRH analogue) — mechanisms, clinical trial data, body composition effects, and selection framework for fat loss research.
A beginner’s guide to GLP-1 receptor agonist peptides for women over 40: how incretin hormones regulate appetite and visceral fat, the evidence from Tirzepatide and Semaglutide trials, and why menopause physiology makes GLP-1 research particularly relevant.
A clear, plain-language explanation of GLP-1 peptides for busy professionals. Covers what GLP-1 is, how these compounds produce weight loss, the evolution from semaglutide to Tirzepatide to Retatrutide, side effect management, and practical considerations before starting research.
An in-depth comparison of Retatrutide (triple agonist) and Tirzepatide (dual GLP-1/GIP agonist) for weight management research. Covers mechanisms, clinical trial data, side effect profiles, muscle preservation strategies, and research considerations.
How Tesamorelin’s GHRH mechanism specifically addresses visceral fat accumulation after menopause. An intermediate research guide covering GH axis decline, FDA trial evidence, comparison with GLP-1 approaches, and metabolic benefits for women over 40.
Retatrutide (LY3437943) is a first-in-class triple GIP/GLP-1/glucagon receptor co-agonist showing 24% weight reduction in Phase 2 trials. This expert guide covers the mechanism, TRIUMPH Phase 3 program, comparison with tirzepatide, and hepatic fat effects.
Tirzepatide is a first-in-class dual GIP/GLP-1 receptor agonist producing 20-22% weight reduction in clinical trials. This intermediate guide covers mechanisms, SURMOUNT trial data, comparison with semaglutide, and metabolic research protocols for men over 40.
